tradingkey.logo

Urogen Announces FDA Advisory Committee For Ugn-102, An Investigational Treatment For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

ReutersMay 7, 2025 1:29 PM

Urogen Pharma Ltd UR8.F:

  • UROGEN ANNOUNCES FDA ADVISORY COMMITTEE FOR UGN-102, AN INVESTIGATIONAL TREATMENT FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER

  • UROGEN PHARMA LTD - FDA SCHEDULES ODAC MEETING FOR UROGEN'S UGN-102 ON MAY 21, 2025

  • UROGEN PHARMA LTD - FDA TARGETS JUNE 13, 2025 FOR UGN-102 REVIEW COMPLETION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI